JP2021534750A5 - - Google Patents

Info

Publication number
JP2021534750A5
JP2021534750A5 JP2021509199A JP2021509199A JP2021534750A5 JP 2021534750 A5 JP2021534750 A5 JP 2021534750A5 JP 2021509199 A JP2021509199 A JP 2021509199A JP 2021509199 A JP2021509199 A JP 2021509199A JP 2021534750 A5 JP2021534750 A5 JP 2021534750A5
Authority
JP
Japan
Prior art keywords
sequence ids
sequence
cancer
antigen
ids
Prior art date
Application number
JP2021509199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534750A (ja
JPWO2020038379A5 (https=
JP7488534B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/101659 external-priority patent/WO2020038379A1/en
Publication of JP2021534750A publication Critical patent/JP2021534750A/ja
Publication of JP2021534750A5 publication Critical patent/JP2021534750A5/ja
Publication of JPWO2020038379A5 publication Critical patent/JPWO2020038379A5/ja
Application granted granted Critical
Publication of JP7488534B2 publication Critical patent/JP7488534B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509199A 2018-08-20 2019-08-20 新規ながん免疫療法抗体組成物 Active JP7488534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720015P 2018-08-20 2018-08-20
US62/720,015 2018-08-20
PCT/CN2019/101659 WO2020038379A1 (en) 2018-08-20 2019-08-20 Novel cancer immunotherapy antibody compositions

Publications (4)

Publication Number Publication Date
JP2021534750A JP2021534750A (ja) 2021-12-16
JP2021534750A5 true JP2021534750A5 (https=) 2022-08-22
JPWO2020038379A5 JPWO2020038379A5 (https=) 2022-08-22
JP7488534B2 JP7488534B2 (ja) 2024-05-22

Family

ID=69591356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509199A Active JP7488534B2 (ja) 2018-08-20 2019-08-20 新規ながん免疫療法抗体組成物

Country Status (12)

Country Link
US (1) US12391758B2 (https=)
EP (1) EP3841126A4 (https=)
JP (1) JP7488534B2 (https=)
KR (1) KR20210046725A (https=)
CN (2) CN116410320A (https=)
AU (1) AU2019324388A1 (https=)
BR (1) BR112021003182A2 (https=)
CA (1) CA3110138A1 (https=)
MX (1) MX2021002077A (https=)
SG (1) SG11202101757QA (https=)
TW (1) TW202016150A (https=)
WO (1) WO2020038379A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023187460A1 (en) * 2022-04-01 2023-10-05 Mabtree Biologics Ag Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function
CN118930652B (zh) * 2024-07-29 2025-03-11 北京肿瘤医院(北京大学肿瘤医院) 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104356236B (zh) * 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2615460A1 (en) * 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
KR101814408B1 (ko) * 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
AU2009333580B2 (en) * 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
NZ628923A (en) * 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
HK1204557A1 (en) 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CA2979219A1 (en) 2015-03-10 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind psma
CA2993177A1 (en) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
CN106432501B (zh) * 2015-08-06 2021-07-30 基石药业 新型抗pd-l1抗体
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EA037855B1 (ru) * 2016-01-29 2021-05-27 Сорренто Терапьютикс, Инк. Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1
CN108350082B (zh) * 2016-06-13 2021-09-24 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
CN106496327B (zh) * 2016-11-18 2019-01-15 昆山百尔泰生物科技有限公司 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体
CN108239149B (zh) * 2016-12-25 2021-03-05 南京传奇生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
CN107973854B (zh) * 2017-12-11 2021-05-04 苏州银河生物医药有限公司 Pdl1单克隆抗体及其应用
US12378295B2 (en) * 2018-10-29 2025-08-05 1Globe Biomedical Co., Ltd. Rationally designed protein compositions

Similar Documents

Publication Publication Date Title
JP2020524174A5 (https=)
JP2021514664A5 (https=)
RU2014106671A (ru) Варианты гуманизированных иммуномодулирующих моноклональных антител
RU2017105915A (ru) Антитела против pd-1
JP2019536430A5 (https=)
JP2020529863A5 (https=)
JP2020515239A5 (https=)
JP2025124799A (ja) 細胞内部移行をモジュレートするための組成物および方法
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2017506067A5 (https=)
JP2018502050A5 (https=)
JP2017530722A5 (https=)
JP2021528047A5 (https=)
CN117946277A (zh) 多特异性抗体及其制备和使用方法
JP2020530777A (ja) 多重特異性抗体とその作製及び使用方法
JP2020530770A5 (https=)
JP2021531255A5 (https=)
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2021501567A5 (https=)
JP2024016024A5 (https=)
JP2019513410A5 (https=)
CN115605513A (zh) 一种抗pd-l1和her2的双特异性抗体
Fan et al. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells
JP2021512652A5 (https=)
CN115916839A (zh) 抗pdl1×egfr的双特异性抗体